Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorPeking University Third Hospital

About this trial

FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease. This prospective study aims to explore the value of 18F-AlF-FAPI PET/CT in assessing the activity of Thyroid Eye Disease (TED) and investigate whether FAPI PET/CT may be superior to 99mTc-DTPA SPECT/CT for the diagnosis, therapy response assessment, and follow-up of TED.

Eligibility criteria

Qualifiers

Age ≥ 18 years;

Patients diagnosed with TED;

Complete understanding and voluntary participation in this study, with the signing of an informed consent form.

Disqualifiers

Severe liver or kidney dysfunction;

Inability to maintain a supine position for 5 minutes to cooperate with the examination;

Suffering from claustrophobia or other psychiatric disorders;

Patients planning pregnancy or in the prenatal or lactation period;

Trial design

Treatments tested in this trial

  • 18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT

Treatment groups

50 Participants
are divided into 1 treatment group